Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Long-term Imiquimod treatment causes initial skin inflammation that lessens over time, and topical corticosteroids reduce this inflammation and cytokines in a mouse model of psoriasis.

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.

Treatment with biologic agents can significantly improve psoriasis symptoms, and blood biomarkers could potentially predict individual patient's response to treatment.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

Tofacitinib may help treat both alopecia areata and inflammatory bowel disease.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Psoriasis patients are willing to pay less than the cost of biologic treatments for remission and don't expect complete or long-term symptom clearance.

Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.

A multi-drug treatment can effectively clear extensive calcinosis in juvenile dermatomyositis.

Cetuximab often causes skin rashes, and managing these is important for cancer treatment.

Dupilumab effectively treated severe alopecia areata in a child.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.

Upadacitinib improved multiple immune-related conditions in one patient.

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

Colectomy led to hair regrowth in a Crohn's patient with alopecia areata.

Ixekizumab effectively treated severe psoriasis and hair loss in a patient.

Ustekinumab might work for severe psoriasis, but more research is needed to be sure.

Bimekizumab quickly improves psoriasis symptoms and skin at the molecular level.

Microvascular damage and platelet issues persist in ulcerative colitis remission, helping assess disease states.

Radiesse is a versatile facial injectable used for cosmetic improvements and long-term collagen production, with careful dosing needed to prevent complications.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Systemic agents like cyclosporine, methotrexate, and acitretin help manage psoriasis but have significant side effects.